New Research Featuring E06

Posted on December 04, 2020


Our first featured research articles were submitted by Dr. Joe Witzum from UCSD. In the work, "Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice", Dr. Witzum and colleagues study the role of oxidized phospholipids in vivo as they relate to atherogenesis using transgenic mice expressing a single-chain variable fragment of E06, E06 is the natural IgM antibody that blocks the uptake of oxidized low-density lipoprotein by macrophages and inhibits the proinflammatory properties of oxidized phospholipids. The study found that mice expressing the E06 fragment had less atherosclerosis after a high-cholesterol diet, decreased cholesterol accumulation and oxLDL uptake, decreased serum amyloid A, and prolonged life as measured over 15 months. When taken together, these findings suggest that therapies aimed at inactivating oxidized phospholipids, such as E06, may reduce generalized inflammation and progression of atherosclerosis.

In a second study, "Neutralizaion of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatisis" Dr. Witzum and colleagues show that oxidized phospholipids accumulate in the blood and liver during Non-alcoholic Steatohepatisis (NASH), and that E06 can be used to neutralize oxidized phospholipids relieving NASH symptoms and liver cancer in mouse models.